Hodgkin's lymphoma in developing countries: can we go further?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Interim Positron Emission Tomography-Adapted Treatment Strategies for Classic Hodgkin Lymphoma: Insights From Korean Real-World Data.Journal of Korean medical science · 2026
   Article
2. Frontline ABVD Remains an Effective Option in Advanced-Stage Classical Hodgkin Lymphoma: Real-World Data from Turkey.Journal of clinical medicine · 2026
   Article
3. The clinical value of interim PET/computed tomography scanning in patients with classical Hodgkin's lymphoma and its influence on prognosis in Duhok Province, Kurdistan Region - Northern Iraq.Nuclear medicine communications · 2026
   Article
4. Subgroup analysis of treatment pathways and clinical outcomes in Hodgkin lymphoma in Latin America from the retrospective B-HOLISTIC study.Scientific reports · 2025
   Observational

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.